The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »GSK
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a…
Read More »